• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lilly, Boehringer’s Basaglar long-acting insulin now available in the U.S.

December 15, 2016 By Sarah Faulkner

Lilly, Boehringer's Basaglar long-acting insulin now available in the U.S.Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus.

The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides guidance for injection using the Basaglar KwikPen, injection demo kits and educational videos.

Several pharmacy benefit managers have chosen Basaglar for their formularies, according to Lilly and Boehringer, so the 2 companies anticipate that it will be widely covered by commercial insurance plans. There will also be a Basaglar savings card for eligible patients.

Lilly and Boehringer won FDA approval for the long-acting insulin in December last year to control high blood sugar in adults and children with type I diabetes, as well as adults with type II diabetes.

“Lilly and Boehringer Ingelheim are proud to bring another proven effective diabetes treatment choice to people who may need a long-acting insulin to help control their blood sugar,” Lilly Diabetes VP of Global Medical Affairs Dr. David Kendall said in prepared remarks. “We know that starting insulin can be a challenging experience for some people with type II diabetes. As part of our continuing commitment to the diabetes community, we are expanding our educational resources.”

Lilly said yesterday that it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans.

Filed Under: Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Eli Lilly & Co., Sanofi-Aventis

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS